Pseudomonas marinoglutinosa

Important Notice: Absence of Evidence for "Pseudomonas marinoglutinosa" as a Dietary Supplement or Natural Health Ingredient

A comprehensive search of peer-reviewed literature (PubMed/PMC), government health body databases (NIH Office of Dietary Supplements, NIH/NCCIH, WHO, EFSA), official pharmacopeias, and rigorous evidence databases (Examine.com) returns no verifiable evidence that Pseudomonas marinoglutinosa — or its valid current and historical equivalents — has ever been used, studied, marketed, or evaluated as a dietary supplement, nutraceutical, or natural health ingredient for human beings. The strict sourcing rules governing this article prohibit the invention or extrapolation of facts, mechanisms, dosages, study results, or traditional-use claims that cannot be verified in authoritative sources. Accordingly, a full encyclopedic article of the type requested cannot be written without fabricating claims. What follows is a fully sourced, accurate account of what this organism actually is, according to the scientific record.

Identity and Taxonomy

Nomenclatural History

The name Pseudomonas marinoglutinosa is a historical, now-invalid bacteriological designation. Early rRNA hybridization studies identified Pseudomonas marinoglutinosa as one of several organisms — alongside Pseudomonas nigrifaciens, Pseudomonas atlantica, Pseudomonas carrageenovora, and Pseudomonas piscicida — that should properly be renamed and placed within the genus Alteromonas based on rRNA cistron similarity. This reclassification moved the organism out of the genus Pseudomonas entirely.

The bacterial genera Alteromonas and Pseudoalteromonas originate from the division of the former genus Alteromonas, which now includes only one species, Alteromonas macleodii, while all other species fall in the genus Pseudoalteromonas. A further reclassification occurred in 2003. The taxonomic position of the marine bacterium Alteromonas marinoglutinosa NCIMB 1770 was investigated in a polyphasic study; analysis of 16S rDNA sequence and DNA–DNA reassociation values confirmed the phylogenetic position of strain NCIMB 1770 within the genus Pseudoalteromonas as a separate species, distinct from all Pseudoalteromonas species with validly described names, and it was proposed that the strain be classified as Pseudoalteromonas mariniglutinosa sp. nov., nom. rev., comb. nov., with the type strain NCIMB 1770^T (=KMM 3635^T).

Therefore, the full sequence of valid names for this organism is: Pseudomonas marinoglutinosa (original, invalid) → Alteromonas marinoglutinosa (intermediate) → Pseudoalteromonas mariniglutinosa (currently accepted valid name, 2003). The name "Pseudomonas marinoglutinosa" does not appear anywhere in regulatory ingredient lists, pharmacopeias, or dietary supplement registries.

Biological Classification

The genus Pseudoalteromonas — to which this organism belongs — includes Gram-negative, heterotrophic, and aerobic marine bacteria, which belong to the Alteromonadales order in the Gammaproteobacteria class. The Pseudoalteromonas strains require a seawater base for growth and are therefore true marine bacteria. Nowadays, 41 species are assigned to this genus and over 3,772 Pseudoalteromonas strains are currently listed in the NCBI taxonomy browser.

Gram-negative bacteria of the genus Pseudoalteromonas are aerobic non-fermentative prokaryotes that are widespread obligatory marine microorganisms and require a seawater base for their growth. The genus has caught the attention of scientists because its members are widely distributed in the marine environment and are associated with a variety of marine organisms such as corals, sponges, mollusks, fishes, tunicates, seawater, sea ice, and sediments, and have been shown to be capable of producing bioactive compounds with antibacterial, antifungal, algicidal, and antifouling activities, as well as a broad profile of enzymatic activity.

Strain KMM 232 and Its Chemical Constituents

Much of the scientific literature referencing the name Pseudoalteromonas marinoglutinosa (or the closely related designation KMM 232) concerns the chemical structure of polysaccharides isolated from this organism's cell surface — work conducted purely within the domain of marine microbiology and structural carbohydrate chemistry, with no dietary supplement application.

A sulfated O-specific polysaccharide containing D-mannose, L-rhamnose, and the sulfate group was obtained by mild acid hydrolysis of lipopolysaccharide (S-form) of the marine bacterium Pseudoalteromonas marinoglutinosa KMM 232. Based on analysis of methylation and ¹³C-NMR spectroscopy of native and desulfated polysaccharides, the disaccharide repeat unit in the O-specific polysaccharide was established; this was the first report of a sulfated O-specific polysaccharide isolated from Gram-negative bacteria.

P. marinoglutinosa KMM 232 was the first Gram-negative bacterium reported to contain a sulfate group in the O-specific polysaccharide. Sulfated group, l-iduronic acid, d-galacto, l-galacto and L-gulo configurations, (R)-lactic acid, and glycerophosphate have all been recognised as the uncommon acidic components of the polysaccharides from Pseudoalteromonas marinoglutinosa KMM 232; the polysaccharide from the mucoid colonies of KMM 232 has a disaccharide repeating unit of 1,3-β-D-Manp and 1,4-α-L-Rhap with sulfate groups at O-2 positions of Rhap.

Common features of most polysaccharides of the genus Pseudoalteromonas are their acidic character and the presence of unusual sugars and non-sugar substituents, with the absence of any structural similarity of the repeating units. The significance of these structures has been investigated primarily in the context of lipopolysaccharide chemistry and bacterial immunology, not human nutrition or supplementation.

Bioactive Compound Profile of the Genus Pseudoalteromonas (Research Context)

Because the literature on P. marinoglutinosa is embedded within the broader genus Pseudoalteromonas, the following describes the research landscape for the genus as a whole. No findings below pertain to P. marinoglutinosa specifically in a health or supplement context, and none represent human clinical evidence for any health benefit.

The bacteria produce a wide range of biologically active compounds, such as antibiotics, toxins and antitoxins, antitumor and antimicrobial agents, as well as enzymes with a wide spectrum of action. Pigmented species of the genus have been shown to produce an array of low and high molecular weight compounds with antimicrobial, anti-fouling, algicidal and various pharmaceutically-relevant activities; compounds formed include toxic proteins, polyanionic exopolymers, substituted phenolic and pyrrole-containing alkaloids, cyclic peptides, and a range of bromine-substituted compounds.

The Pseudoalteromonas genus harbors one of the highest proportions of bacterial species producing antimicrobial molecules. Microorganisms from the Pseudoalteromonas genus are well-known producers of several metabolites with antimicrobial activity, such as alkaloids, polyketides, peptides, and proteins.

In terms of antitumor potential at the genus level, in order to exploit the rich reservoir of marine cold-adapted bacteria as a source of bioactive metabolites, ethyl acetate crude extracts of thirteen polar marine bacteria were tested for their antiproliferative activity on A549 lung epithelial cancer cells; the crude extract from Pseudoalteromonas haloplanktis TAC125 was the most active in inhibiting cell proliferation, and extensive bioassay-guided purification and mass spectrometric characterization allowed the identification of 4-hydroxybenzoic acid (4-HBA) as the molecule responsible for this bioactivity. This work is in vitro and species-specific; it does not involve P. marinoglutinosa and does not constitute clinical evidence.

Regarding the genus's ecological and pharmaceutical significance: ecologically, Pseudoalteromonas has been shown to influence biofilm formation in various marine econiches, to be involved in predator-like interactions within the microbial loop, to influence settlement, germination, and metamorphosis of various invertebrate and algal species, and may also be adopted by marine flora and fauna as defensive agents. These are ecological roles, not human health applications.

Traditional and Historical Use

No traditional use of Pseudomonas marinoglutinosa, Alteromonas marinoglutinosa, or Pseudoalteromonas mariniglutinosa by any human culture, in any time period, for any medicinal or nutritional purpose, has been identified in authoritative sources. This organism is a marine bacterium with no documented history of deliberate human consumption, ethnobotanical use, or incorporation into any traditional pharmacopoeia.

Regulatory and Safety Status

No entry for Pseudomonas marinoglutinosa, Alteromonas marinoglutinosa, or Pseudoalteromonas mariniglutinosa appears in the NIH Office of Dietary Supplements ingredient databases, the WHO or EFSA authorized substance lists, the European Pharmacopoeia, the USP, ESCOP monographs, or the German Commission E monographs. These organisms are therefore not recognized as dietary supplement ingredients by any major regulatory body.

Regarding the safety profile of the genus more broadly: allowing for rare exceptions, Pseudoalteromonas strains are associated with healthy animals or algae; few strains are known as pathogenic or opportunistic; Flavobacterium piscicida, reclassified as P. piscicida, is involved in flavobacteriosis in farm fish, while P. agarivorans NW4327 was recently reported as pathogenic for the sponge Rhopaloeides odorabile. Some species of Pseudoalteromonas have been rarely implicated as opportunistic pathogens of marine animals including fish and crustacea; this pathogenicity may relate to lipopolysaccharide and other heat-labile factors and other virulence determinants such as hemolysins and thrombolysins.

The lipopolysaccharide (LPS) component of Gram-negative bacteria, including Pseudoalteromonas species, is a known endotoxin. Bacterial lipopolysaccharides are major components of the outer surface of Gram-negative bacteria and are often of interest in medicine for their immunomodulatory properties; in small amounts they can be beneficial, but in larger amounts they may cause endotoxic shock. No human safety data, acceptable daily intake, tolerable upper intake level, or toxicological evaluation specific to P. marinoglutinosa is available in the peer-reviewed or regulatory literature.

Scientific Evidence by Proposed Area of Use

Because no authoritative source documents Pseudomonas marinoglutinosa (or its reclassified equivalents) as a dietary supplement ingredient, there are no human clinical trials, controlled studies, systematic reviews, or meta-analyses evaluating its efficacy or safety in any health indication. No dosage forms, dose ranges, or formulations for human administration appear in any peer-reviewed study or regulatory submission. There is no evidence base to characterize — whether for immune support, antimicrobial applications, gut health, or any other indication.

The in vitro and ecological research on Pseudoalteromonas species broadly — including work on antimicrobial compounds, sulfated polysaccharides, and antitumor metabolites — does not constitute evidence of supplement efficacy and cannot be responsibly extrapolated to claims about P. marinoglutinosa as a consumable ingredient.

Conclusion

"Pseudomonas marinoglutinosa" is a historical taxonomic synonym, now obsolete, for a marine bacterium currently known as Pseudoalteromonas mariniglutinosa. It is not a dietary supplement ingredient, has no documented traditional use, no regulatory approval in any jurisdiction as a consumable substance, no human clinical trials, no established dosage, and no pharmacopeial monograph. Its scientific interest lies exclusively within marine microbiology and structural carbohydrate chemistry. Any product or publication presenting this organism as a dietary supplement ingredient with characterized health benefits, dosages, or traditional uses would not be supportable by peer-reviewed or regulatory evidence.

References

• Romanenko et al. (2003). Assignment of 'Alteromonas marinoglutinosa' NCIMB 1770 to Pseudoalteromonas mariniglutinosa sp. nov., nom. rev., comb. nov. International Journal of Systematic and Evolutionary Microbiology, 53(4):1105–1109.
• PubMed: Romanenko et al. (2003). PMID: 12892134.
• ScienceDirect Topics: Pseudoalteromonas — Overview (Elsevier).
• ScienceDirect Topics: Pseudoalteromonas (Biochemistry/Molecular Biology — Elsevier).
• Bowman JP (2007). Bioactive Compound Synthetic Capacity and Ecological Significance of Marine Bacterial Genus Pseudoalteromonas. Marine Drugs, 5(4):220–241.
• PubMed: Bowman JP (2007). PMID: 18463726.
• Offret et al. (2016). Spotlight on Antimicrobial Metabolites from the Marine Bacteria Pseudoalteromonas: Chemodiversity and Ecological Significance. Marine Drugs, 14(7):129.
• Komandrova et al. (1998). Structure of sulfated O-specific polysaccharide of the marine bacterium Pseudoalteromonas marinoglutinosa KMM 232. Biochemistry (Moscow), 63(10):1200–1204 [cited in ResearchGate].
• Fondi et al. (2018). Pseudoalteromonas haloplanktis TAC125 produces 4-hydroxybenzoic acid that induces pyroptosis in human A459 lung adenocarcinoma cells. Scientific Reports.
• Andreo-Vidal et al. (2018). The Pseudoalteromonas luteoviolacea L-amino Acid Oxidase with Antimicrobial Activity Is a Flavoenzyme. Marine Drugs, 16(12):499. PMC6316408.
• Atencio et al. (2018). Antimicrobial-producing Pseudoalteromonas from the marine environment of Panama shows high phylogenetic diversity and clonal structure. Journal of Basic Microbiology.
• Ivanova & Mikhailov (2001). A New Family, Alteromonadaceae fam. nov., Including Marine Proteobacteria of the Genera Alteromonas, Pseudoalteromonas, Idiomarina, and Colwellia. Microbiology.
• Con et al. (2010). Highly Brominated Antimicrobial Metabolites from a Marine Pseudoalteromonas sp. PMC2993825.
• Ficko-Blean et al. (2018). Evolutionary Evidence of Algal Polysaccharide Degradation Acquisition by Pseudoalteromonas carrageenovora 9T to Adapt to Macroalgal Niches. Frontiers in Microbiology.
• Mulet et al. (2009). Historical evolution and current status of the taxonomy of genus Pseudomonas. Infection, Genetics and Evolution. PMID: 19712752.